Vähämurto P, et al. - In this population-based study, researchers focused on the clinical features, including cell of origin, clinical presentation, as well as on survival following rituximab (R) and central nervous system (CNS) directed chemotherapy in patients with sinonasal tract diffuse large B-cell lymphoma (SNT-DLBCL). Germinal centre B-cell phenotype was detected in 32% of the patients. With CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOP-like chemotherapy, 46 patients were treated with curative intent, 21 (46%) before and 25 (54%) in the R-era. CNS-directed chemotherapy was chosen to treat 24 patients (52%). Attenuation in the risk of progression and death and better survival were observed in association with R added to chemotherapy. Findings highlighted the beneficial therapeutic impacts of rituximab and CNS-directed chemotherapy in patients with SNT-DLBCL.